PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.
The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.
Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.
Get in-depth analysis and insight on investing in the high-stakes Biotech and Pharma sectors. Check out RTT Biotech Investor and our Biotech Home Page.
ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.
March 31, 2026 15:49 ET In this week’s video, we’ll cover major biotech moves and breakthroughs - from Novartis and Merck’s blockbuster acquisitions to the first new Hunter syndrome therapy in two decades. We’ll also look at a promising alternative to daily insulin injections and the near-term catalyst for Q3 Bio, which has been hitting new 52-week highs.
A recent case report revealed that an 80-year-old woman with Alzheimer's disease showed improvements in her cognitive abilities after receiving several doses of psilocybin-containing mushrooms. The report, published in the journal Frontiers in late May, focused on a Japanese American woman who has...
Giving babies eggs early in life may help reduce their risk of developing egg allergies, especially for infants with eczema, according to a new study. The study, conducted by researchers from The University of Queensland and Murdoch Children's Research Institute, analyzed data from more than 7,200...
Chinese researchers have carried out the world's first transplant of two pig kidneys and a pig liver into a 53-year-old brain-dead man at the same time, marking an important step forward in xenotransplantation. The surgery was conducted at the Second Affiliated Hospital of Guangxi Medical University...
the CRL for its NDA of bitopertin in erythropoietic protoporphyria (EPP). The company confirmed alignment with the FDA that the ongoing Phase 3 APOLLO study, if successful, can serve as the basis for a CRL response and potentially support a traditional approval.